The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
Open accessAbstract
We describe the 2-year follow-up of an open-label trial (CT-AMT-011-01) of AAV1-LPL(S447X) gene therapy for lipoprotein lipase (LPL) deficiency (LPLD), an orphan disease associated with chylomicronemia, severe hypertriglyceridemia, metabolic complications and potentially life-threatening pancreatitis. The LPL(S447X) gene variant, in an adeno-associated viral vector of serotype 1 (alipogene tiparvovec), was administered to 14 adult LPLD patients with a prior history of pancreatitis. Primary objectives were to assess the long-term safety of alipogene tiparvovec and achieve a ≥40% reduction in fasting median plasma triglyceride (TG) at 3-12 weeks compared with baseline. Cohorts 1 (n=2) and 2 (n=4) received 3 × 10(11) gc kg(-1), and cohort 3 (n=8) received 1 × 10(12) gc kg(-1). Cohorts 2 and 3 also received immunosuppressants from the time of alipogene tiparvovec administration and continued for 12 weeks. Alipogene tiparvovec was well tolerated, without emerging safety concerns for 2 years. Half of the patients demonstrated a ≥40% reduction in fasting TG between 3 and 12 weeks. TG subsequently returned to baseline, although sustained LPL(S447X) expression and long-term changes in TG-rich lipoprotein characteristics were noted independently of the effect on fasting plasma TG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A triple regimen of ciclosporin, mycophenolate and corticosteroids was used in patients receiving high vector doses (Gaudet et al., 2012), an established immunosuppression regimen used to prevent solid organ transplant rejection (Nelson et al., 2022). Initially, transient T cell activation was still seen in 64 % of patients.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Gaudet et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“The fi rst approved AAV gene therapy drug was Glybera for treating lipoprotein lipase de fi ciency using AAV1 vector (7), which was approved in Europe in 2012.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [7]
In the citing paper
“In all patients, anti-AAV antibodies were not affected by immunosuppressants, and T cell response was observed in most patients (7).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [7]
In the citing paper
“Unfortunately, TG drifted back to baseline levels within 6 months, although a few exceptional cases experienced sustained benefits.84–87”
From Clinical review on triglycerides (2020) · cites this paper as [84]
In the citing paper
“Spinal anaesthesia was needed for intramuscular injections of the adeno-associated virus subtype 1 vector carrying hyperfunctional LPL p.S447X; TG normalized within 12 weeks.84–86”
From Clinical review on triglycerides (2020) · cites this paper as [84]
In the citing paper
“FCH has no monogenic component and is not linked to a single genetic cause, but the phenotype is high LDL-C and/or high TGs [358,359].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [359]
In the citing paper
“Recently, gene therapy for LPL deficiency has been developed and tested in clinical trials 305 and the alipogene tiparvovec was approved by the EMA in 2013.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [305]
In the citing paper
“In the initial regimen, 9/14 subjects showed humoral and cellular response against rAAV1 (77).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [77]
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-5-839_2 · Cited by 1,320
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,029
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J. R., Irvine, S. A., & Ramji, D. P. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 962
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
(1995) · PubMed · Cited by 423
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Benlian, P., Gennes, J. L. D., Foubert, L., Zhang, H., Gagné, S., & Hayden, M. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351203 · Cited by 296
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 404
Neelamekam, S., Kwok, S., Malone, R., Wierzbicki, A. S., & Soran, H. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0706-1 · Cited by 20
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Xie, Y., Wang, J., He, Y., Yu, X.-M., Zheng, Q., Ling, C., Feng, X.-L., & Zhu, L. (2022) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2022.10.003 · Cited by 19
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy
MUÑOZ, S. A., Bertolin, J., Jiménez, V., Jaén, M. L., García, M., Pujol, A., Vilà, L., Sacristan, V., Barbon, E., Ronzitti, G., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101899 · Cited by 20
Gene-based therapies in lipidology
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
Self-citationGene Replacement Therapy for Genetic Hepatocellular Jaundice
van Dijk, R., Beuers, U. H., & Bosma, P. J. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8454-7 · Cited by 19
Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model
Greig, J. A., Jennis, M., Dandekar, A. P., Chorazeczewski, J. K., Smith, M. K., Ashley, S. N., Yan, H., & Wilson, J. M. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.08.003 · Cited by 18
Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy
Franke, A., Hardet, R., Prager, L., Bentler, M., Demeules, M., John-Neek, P., Jäschke, N. M., Ha, T. C., Hacker, U. T., Adriouch, S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.010 · Cited by 18
Gene Therapy Strategies for the Treatment of Spinal Cord Injury
Uchida, K., Nakajima, H., Guerrero, A. R., Johnson, W. E., Masri, W. E., & Baba, H. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.20 · Cited by 18
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Self-citationViral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 19
Progress toward improved therapies for inborn errors of metabolism
Ginocchio, V. M., & Brunetti‐Pierri, N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv418 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Egorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 18
Wu, M. J., Wolska, A., Roberts, B. S., Pearson, E. M., Gutgsell, A. R., Remaley, A. T., & Neher, S. B. (2018) · Journal of Lipid Research · doi:10.1194/jlr.d086793 · Cited by 16
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationRegulatory Oversight of Cell and Gene Therapy Products in Canada
Ridgway, A. A. G., Agbanyo, F. R., Wang, J., & Rosu‐Myles, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18618-4_3 · Cited by 17
Nambiar, B., Sookdeo, C., Berthelette, P., Jackson, R., Piraino, S., Burnham, B. L., Nass, S., Souza, D. W., O’Riordan, C. R., Vincent, K. A., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.124 · Cited by 17
Effects of Thermally Induced Configuration Changes on rAAV Genome’s Enzymatic Accessibility
Xu, Y., Guo, P., Zhang, J., Chrzanowski, M., Chew, H., Firrman, J., Sang, N., Diao, Y., & Xiao, W. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.005 · Cited by 17
A comprehensive study of AAV tropism across C57BL/6 mice, BALB/c mice, and crab-eating macaques
Fang, K., Yang, X., Liu, Y., Xia, J., Wu, R., Yang, F., Feng, C., Liu, X., Shi, L., Geng, G., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101434 · Cited by 16
Biosafety Practices for In Vivo Viral-Mediated Gene Therapy in the Health Care Setting
Blind, J. E., McLeod, E. N., Brown, A. M., Patel, H., & Ghosh, S. (2020) · Applied Biosafety · doi:10.1177/1535676020942195 · Cited by 16
Hypertriglyceridemic pancreatitis
de Pretis, N., Marchi, G. D., & Frulloni, L. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02641-2 · Cited by 16
Shamshad, A., Kang, C., Jenny, L. A., Persad‐Paisley, E. M., & Tsang, S. H. (2023) · Vision Research · doi:10.1016/j.visres.2023.108258 · Cited by 16
Yuan, C., Yao, X., Lu, G., Hu, Y., Mao, W., Ke, L., Tong, Z., Xia, Y., Ma, S., Dong, X., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.018 · Cited by 16
Hu, S. W., Lv, J., Wang, Z., Tang, H., Wang, H., Wang, F., Wang, D., Zhang, J., Zhang, L., Cao, Q., et al. (2024) · Research · doi:10.34133/research.0341 · Cited by 18
AAV-Mediated Gene Therapy for Atherosclerosis
Lehrke, M., & Lebherz, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0434-0 · Cited by 16
Interaction of vectors and parental viruses with the host genome
Gil-Fariña, I., & Schmidt, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.004 · Cited by 17
Singh, M., Brööks, A. G., Toofan, P., & McLuckie, K. (2023) · Gene Therapy · doi:10.1038/s41434-023-00417-x · Cited by 16
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Lytvyn, V., Mercier, M., Fatehi, D., Lin, W., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.075 · Cited by 16
Yang, C., Tian, W., Ma, S., Guo, M., Lin, X., Gao, F., Dong, X., Gao, M., Wang, Y., Liu, C., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.011 · Cited by 15
Aljouda, L., Nagy, L. L., & Schulze, A. (2023) · Nutrients · doi:10.3390/nu15163535 · Cited by 14
Promising tools for future drug discovery and development in antiarrhythmic therapy
Mondéjar‐Parreño, G., Sánchez-Pérez, P., Cruz, F. M., & Jalife, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001297 · Cited by 14
Yamada, M., Suzuki, J., Sato, S., Zenimaru, Y., Saito, R., Konoshita, T., Kraemer, F. B., & Ishizuka, T. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100194 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Lipoprotein lipase gene polymorphism rs1059611 functionally influences serum lipid concentrations
Mo, X., Liu, X., Wang, L., Li, H., Lu, X., Huang, J., Chen, J., Cao, J., Li, J., Chen, S., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.005 · Cited by 15
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Recent progress in gene therapy for familial hypercholesterolemia treatment
Luo, Y., Hou, Y., Zhao, W., & Yang, B. (2024) · iScience · doi:10.1016/j.isci.2024.110641 · Cited by 13
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future
Hajhosseiny, R., Sabir, I. N., Khavandi, K., & Wierzbicki, A. S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.76 · Cited by 13
Frijlink, H. W., Touw, D. J., & Woerdenbag, H. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-15814-3_16 · Cited by 13
Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions
Yeung, K., Suh, K., Garrison, L. P., & Carlson, J. J. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.012 · Cited by 13
Gernoux, G., Guilbaud, M., Devaux, M., Journou, M., Pichard, V., Jaulin, N., Léger, A., Duff, J. L., Deschamps, J., Guiner, C. L., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.003 · Cited by 13
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 15
Long noncoding RNAs induced control of ferroptosis: Implications in cancer progression and treatment
Shi, W., & Sethi, G. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30992 · Cited by 13
Wagner, A., Röhrs, V., Kedzierski, R., Fechner, H., & Kurreck, J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.095 · Cited by 14
Tremblay, J. P., Xiao, X., Aartsma-Rus, A. M., Barbas, C. F., Blau, H. M., Bogdanove, A. J., Boycott, K. M., Braun, S., Breakefield, X. O., Bueren, J. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.4 · Cited by 12
Self-citationLarge-Scale Clinical Manufacturing of AAV Vectors for Systemic Muscle Gene Therapy
Clément, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_15 · Cited by 12
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Role of Essential Metal Ions in AAV Vector-Mediated Transduction
Rambhai, H. K., Ashby, F. J., Qing, K., & Srivastava, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.019 · Cited by 11
Gene Therapy: An Overview of Approved and Pipeline Technologies
Sinclair, A., Islam, S., & Jones, S. M. (2018) · Cited by 11
Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies
von Jonquières, G., Rae, C. D., & Housley, G. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661857 · Cited by 12
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
The Use of Orlistat in an Adult with Lipoprotein Lipase Deficiency: A Case Report
Jarrett, Z. S., Kou, C.-T. J., Wan, W., & Colburn, J. A. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2021.11.004 · Cited by 10
Dead Cas(t) light on new life: CRISPRa-mediated reprogramming of somatic cells into neurons
Zhou, M., Cao, Y., Sui, M., Shu, X., Wan, F., & Zhang, B. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04324-z · Cited by 10
Comparative Next-Generation Sequencing of Adeno-Associated Virus Inverted Terminal Repeats
Petri, K., Fronza, R., Gabriel, R., Kaeppel, C., Nowrouzi, A., Linden, R. M., Henckaerts, E., & Schmidt, M. (2014) · BioTechniques · doi:10.2144/000114170 · Cited by 10
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 14
Meyer, N., Davulcu, O., Xie, Q., Silveria, M., Zane, G. M., Large, E. E., & Chapman, M. S. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3513 · Cited by 9
Kassner, U., Dippel, M., & Steinhagen‐Thiessen, E. (2017) · Der Internist · doi:10.1007/s00108-017-0234-z · Cited by 9
Damerval, M., Fagnoni-Legat, C., Louvrier, A., Fischer, S., Limat, S., Clairet, A., Nerich, V., Madelaine, I., & Kroemer, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.713047 · Cited by 9
Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia
Bell, T. A., Graham, M. J., Baker, B. F., & Crooke, R. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.7 · Cited by 9
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9
Translational Aspects of Adeno-Associated Virus–Mediated Cardiac Gene Therapy
Ziegler, T., Ishikawa, K., Hinkel, R., & Kupatt, C. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.229 · Cited by 9
Szabó, E., & Ambrus, A. (2023) · Biologia Futura · doi:10.1007/s42977-023-00155-6 · Cited by 8
Gene therapy for hereditary hearing loss
Fu, Z., Zhao, L., Guo, Y., & Yang, J. (2024) · Hearing Research · doi:10.1016/j.heares.2024.109151 · Cited by 8
In situproduction of therapeutic monoclonal antibodies
Suscovich, T. J., & Alter, G. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001375 · Cited by 9
Bona, D. D., Cefalu, A. B., Scirè, E., Lima, G. M., Rizzo, C., Giammanco, A., Barbagallo, C. M., Averna, M. R., Rizzo, S., & Caruso, C. (2015) · Transfusion · doi:10.1111/trf.13400 · Cited by 8
Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias
Grützmacher, P., Kleinert, C., Dorbath, C., & Öhm, B. (2015) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-015-0070-4 · Cited by 8
Iizuka, S., Sakurai, F., Tachibana, M., Ohashi, K., & Mizuguchi, H. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.001 · Cited by 8
Hypertriglyceridemia-Induced Acute Pancreatitis
Park, J. M. (2017) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2017.22.4.158 · Cited by 8
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention
Benes, L. B., Brandt, D. J., Brandt, E. J., & Davidson, M. H. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1079-3 · Cited by 8
Severe Familial Hypertriglyceridemia: Successful Treatment With Insulin and a Modified Meal Plan
Ayyavoo, A., Raghupathy, P., Agarwal, M., & Hofman, P. L. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00299 · Cited by 8
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Gingras, R., Mullick, A., Drouin, S., Sasseville, M., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00524-x · Cited by 8
Use of a three-dimensional humanized liver model for the study of viral gene vectors
Wagner, A., Röhrs, V., Dehne, E., Hiller, T., Kedzierski, R., Fechner, H., Lauster, R., & Kurreck, J. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.08.012 · Cited by 7
Managing of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
Gene based therapies for kidney regeneration
Janssen, M. J., Arcolino, F. O., Schoor, P., Kok, R. J., & Mastrobattista, E. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.07.037 · Cited by 9
Kuroda, M., Saitō, Y., Aso, M., & Yokote, K. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00786 · Cited by 7
Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management
de Pretis, N., Amodio, A., & Frulloni, L. (2019) · Herald of Pancreatic Club · doi:10.33149/vkp.2019.01.02 · Cited by 7
Gene Delivery in Lipid Research and Therapies
Giorgi, M. D., & Lagor, W. R. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-62 · Cited by 7
Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells
Deng, X., Zou, W., Yan, Z., & Qiu, J. (2020) · Genes · doi:10.3390/genes11040439 · Cited by 7
Application of Genetic Engineering in Biotherapeutics Development
Schweickert, P. G., & Cheng, Z. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09411-6 · Cited by 8
Kwon, H.-J., Qing, K., Ponnazhagan, S., Wang, X.-S., Markusic, D. M., Gupte, S., Boye, S. E., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.018 · Cited by 6
Kumar, V., Kalishwaralal, K., Chauhan, C., Singh, G., Barnwal, R. P., & Sharma, S. K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1678325 · Cited by 6
Recombinant AAV vaccine expressing PEDV S1 enhances immunity with superior neonatal protection
Pang, M., Ren, M., Jiang, D., Tu, T., Zhou, Y. L., & Wang, Y. (2025) · npj Vaccines · doi:10.1038/s41541-025-01248-0 · Cited by 6
Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome
Benes, L. B., Brandt, E. J., & Davidson, M. H. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1419863 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Dyslipidaemia: what’s around the corner?
Wierzbicki, A. S., Perera, D., & Ewang-Emukowhate, M. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s41 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 6
Gene Therapy for Hypercholesterolemia
Huff, M. W., Assini, J. M., & Hegele, R. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.304800 · Cited by 6
Kim, C. H., Oliver, C., Dar, H. Y., Drissi, H., & Presciutti, S. M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.12.009 · Cited by 6
Ethical Implications of the Cost of Molecularly Targeted Therapies
Flotte, T. R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29010.trf · Cited by 6
History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry
Ariën, A., & Stoffels, P. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch1 · Cited by 6
Characteristics, Recombination Methods, and Applications Progresses of Split-Cas9 System
Liu, Z., Huang, L., Deng, H., Chen, Y., & Xiao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.223 · Cited by 5
Soula, A., Leseigneur, F., Anwar, A., Ozdoganoglu, B., Gurung, J., Bhatti, H. S., Guenat, J., Bazot, Q., Sayed, M. E. E., Ricardo, C. P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101496 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Viral Vectors in Gene Therapy and Clinical Applications
Mahoney, A. L. G., Nassif, N. T., O’Brien, B. A., & Simpson, A. M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102559 · Cited by 5
Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals
Ru, Q., Li, W., Wang, X., Zhang, S., Chen, L., Zhang, Y., Ge, Y. C., Zu, Y., Liu, Y., & Zheng, D. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.12 · Cited by 5
Loozen, L. D., Kruyt, M. C., Vandersteen, A., Kragten, A. H. M., Croes, M., Öner, F. C., & Alblas, J. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2018.0032 · Cited by 5
Moving Forward Toward a Cure for Hemophilia B
VandenDriessche, T., & Chuah, M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.56 · Cited by 5
Metadata
- Authors
- Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., Sier-Ferreira, V, & van Deventer, S.
- Affiliations
- Hôpital de Chicoutimi (CA)
- Corresponding author
- Gaudet, D
- Venue
- Gene Therapy
- Published
- 2012-06-21
- Volume
- 20
- Issue
- 4
- Pages
- 361-369
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC4956470
- OpenAlex
- W2067074806
- Cited by
- 404
- References
- 40
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 17 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 32 · 2019: 33 · 2018: 31 · 2017: 38 · 2016: 33 · 2015: 50 · 2014: 40 · 2013: 25 · 2012: 4
- FWCI
- 24.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Canada Research Chairs
- Health Canada
- Canadian Institutes of Health Research (82941_1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- lipoprotein lipase deficiency, long-term safety, hypertriglyceridemia, triglyceride-rich lipoproteins, immunosuppression, pancreatitis, chylomicronemia
- MeSH terms
- Dependovirus, Adult, Drug Tolerance, Fasting, Female, Humans, Immunosuppressive Agents, Lipoprotein Lipase, Hyperlipoproteinemia Type I, Male, Middle Aged, Pancreatitis, Prospective Studies, Triglycerides, Genetic Therapy, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
